Eravacycline NEW
| Price | $3620 | $4780 | $6700 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Eravacycline | CAS No.: 1207283-85-9 |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Eravacycline |
| Description | Eravacycline (TP-434) is a potent and broad-spectrum antibacterial agent. |
| In vitro | Eravacycline dihydrochloride is a synthetic antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It exhibits broad-spectrum activity against gram-negative bacteria, excluding P. aeruginosa, and demonstrates exceptional efficacy against major gram-positive pathogens, including methicillin-resistant S. aureus. Eravacycline also shows potent inhibition of the ribosome. It is effective against 90% of bacterial isolates (MIC90) across various species panels at concentrations from ≤0.008 to 2 μg/mL, except for Pseudomonas aeruginosa and Burkholderia cenocepacia, which have MIC90 values of 32 μg/mL for both. The compound is active against multidrug-resistant organisms, even those exhibiting extended-spectrum β-lactamases and resistance to carbapenems. Notably, eravacycline is a potent agent against A. baumannii, even against strains resistant to sulbactam, imipenem/meropenem, levofloxacin, and amikacin/tobramycin. It outperforms comparative antibiotics from the tetracycline class, levofloxacin, amikacin, tobramycin, and colistin, with MIC50/90 values of 0.5/1 mg/L. Moreover, it inhibits six E. coli strains with MICs ranging from 0.125 to 0.25 mg/L[1]. |
| In vivo | Mice received eravacycline doses escalating twofold (3.125 to 50 mg/kg) bi-daily. The average fAUC/MIC values indicating net stasis and a 1-log kill were 27.97±8.29 and 32.60±10.85, respectively[2]. Eravacycline showed effectiveness in various murine infection models targeting significant Gram-positive and Gram-negative bacteria. In septicemia models using mice, eravacycline achieved a 50% protective dose at ≤1 mg/kg daily against S. aureus, including methicillin-resistant S. aureus (MRSA) and tetracycline-resistant strains, and S. pyogenes. The PD50 for E. coli ranged from 1.2 to 4.4 mg/kg daily[5]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | Eravacycline | TP 434 | TP434 |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Kanamycin sulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | Dimethyl sulfoxide | Crystal Violet |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2024-12-13 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-08-04 | |
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-08-16 | |
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-01 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY